Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133626 · ClinicalTrials.gov registry record · Phase 3
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
NCT01133626 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 107 participants.
The verdict
NCT01133626, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
Interventions
- DRUG Beclomethasone dipropionate
- DRUG Placebo Nasal Aerosol
- DRUG Prednisone capsules
- DRUG Placebo Prednisone Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133626
The ClinicalTrials.gov registry entry for NCT01133626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Beclomethasone dipropionate is the first listed.
NCT01133626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01133626 about?
NCT01133626 is a clinical study titled "Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)". The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
What is the current status of trial NCT01133626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2010-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01133626?
The interventions under investigation include: Beclomethasone dipropionate (DRUG), Placebo Nasal Aerosol (DRUG), Prednisone capsules (DRUG), Placebo Prednisone Capsules (DRUG).
Who is sponsoring clinical trial NCT01133626?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.